Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus TRAVATAN Z.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus TRAVATAN Z.
TRAVATAN vs TRAVATAN Z
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by binding to FP receptors in the ciliary muscle and trabecular meshwork, leading to matrix metalloproteinase activation and remodeling of extracellular matrix.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop in the affected eye(s) once daily in the evening. Ophthalmic solution 0.004% (travoprost 0.04 mg/mL).
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Terminal elimination half-life is 45 minutes; due to rapid hydrolysis to active acid, the clinical effect duration is longer than the half-life suggests.
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Primarily eliminated via hepatic metabolism; renal excretion of metabolites accounts for approximately 20% of the dose; fecal excretion is minimal.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog